PNPLA3 and metabolic dysfunction-associated steatotic liver disease: In Model 3, weight gain ≥10 kg after age 20 (adjusted OR = 5.65, 95%CI: 3.93–8.13, P = 9.1×10−21), ALT elevation (adjusted OR = 5.31, 95%CI: 3.34–8.45, P = 1.7×10−12), gender (adjusted OR = 2.60, 95%CI: 1.69–3.99, P = 1.3×10−5), dyslipidemia (adjusted OR = 1.98, 95%CI: 1.37–2.87, P = 0.0002), PNPLA3 rs738409 (adjusted OR = 1.98, 95%CI: 1.28–3.04, P = 0.0019) and hypertension (adjusted OR = 1.62, 95%CI: 1.09–2.40, P = 0.0156) were independent predictors for NAFLD.